JMP Securities Increases Sarepta Therapeutics Inc. (SRPT) Price Target to $90.00
Sarepta Therapeutics Inc. (NASDAQ:SRPT) had its target price boosted by stock analysts at JMP Securities from $60.00 to $90.00 in a research report issued to clients and investors on Wednesday. The firm presently has an “outperform” rating on the stock. JMP Securities’ price objective suggests a potential upside of 47.59% from the company’s current price.
Other analysts have also recently issued research reports about the company. Oppenheimer Holdings Inc. lifted their price target on Sarepta Therapeutics from $60.00 to $76.00 in a report on Monday, September 19th. WBB Securities restated a “buy” rating and issued a $40.00 price target on shares of Sarepta Therapeutics in a report on Wednesday, June 8th. Vetr upgraded Sarepta Therapeutics from a “strong sell” rating to a “buy” rating and set a $17.28 price target for the company in a report on Thursday, June 2nd. Robert W. Baird restated a “buy” rating on shares of Sarepta Therapeutics in a report on Friday, June 10th. Finally, Needham & Company LLC lifted their price target on Sarepta Therapeutics from $20.00 to $26.00 and gave the company a “buy” rating in a report on Friday, July 22nd. One research analyst has rated the stock with a sell rating, five have issued a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Sarepta Therapeutics presently has a consensus rating of “Buy” and an average target price of $50.28.
Shares of Sarepta Therapeutics (NASDAQ:SRPT) opened at 60.98 on Wednesday. The firm’s market cap is $2.92 billion. Sarepta Therapeutics has a one year low of $8.00 and a one year high of $63.73. The company has a 50-day moving average of $34.86 and a 200 day moving average of $23.51.
Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings results on Tuesday, July 19th. The company reported ($1.35) EPS for the quarter, missing the consensus estimate of ($1.19) by $0.16. During the same quarter in the prior year, the firm posted ($0.87) earnings per share. On average, equities research analysts expect that Sarepta Therapeutics will post ($4.13) EPS for the current fiscal year.
In related news, VP Jayant Aphale sold 35,000 shares of the company’s stock in a transaction that occurred on Monday, September 19th. The stock was sold at an average price of $50.00, for a total transaction of $1,750,000.00. Following the sale, the vice president now directly owns 21,490 shares of the company’s stock, valued at approximately $1,074,500. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Edward M. Md Kaye sold 24,557 shares of the company’s stock in a transaction that occurred on Wednesday, September 14th. The shares were sold at an average price of $30.00, for a total value of $736,710.00. Following the sale, the chief executive officer now directly owns 76,983 shares in the company, valued at $2,309,490. The disclosure for this sale can be found here. 10.90% of the stock is owned by company insiders.
Several large investors have recently bought and sold shares of the stock. Teacher Retirement System of Texas raised its stake in Sarepta Therapeutics by 13.6% in the second quarter. Teacher Retirement System of Texas now owns 6,034 shares of the company’s stock valued at $115,000 after buying an additional 724 shares in the last quarter. Advisor Group Inc. purchased a new stake in Sarepta Therapeutics during the second quarter valued at about $154,000. Quantitative Systematic Strategies LLC purchased a new stake in Sarepta Therapeutics during the second quarter valued at about $211,000. First Allied Advisory Services Inc. raised its stake in Sarepta Therapeutics by 6.7% in the second quarter. First Allied Advisory Services Inc. now owns 12,800 shares of the company’s stock valued at $245,000 after buying an additional 800 shares in the last quarter. Finally, National Planning Corp raised its stake in Sarepta Therapeutics by 2.1% in the first quarter. National Planning Corp now owns 13,678 shares of the company’s stock valued at $242,000 after buying an additional 275 shares in the last quarter. 72.09% of the stock is currently owned by institutional investors and hedge funds.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.
Receive News & Stock Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related stocks with our FREE daily email newsletter.